A new tuberculosis vaccine will be tested on volunteers at the end of 2025, with plans to submit documents for its registration with the Ministry of Health in 2026, Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology, told TASS. "Currently, this is the most important direction of our work and the most crucial problem for modern medicine. I believe that the creation of a new tuberculosis drug, which at the initial stages would work alongside BCG, and over time, I think, would replace BCG, is in the third stage of clinical trials," said Gintsburg. "And at the end of 2025, if everything goes according to plan, which it is so far, several thousand test subjects will be vaccinated with this new vaccine that prevents tuberculosis infection." In addition, drugs protecting against pertussis and six strains of rotavirus are being developed. Scientists are also trying to create broadly specific antibodies. These will enable not only the creation of vaccines against COVID-19 and influenza, which will not need to be changed annually, but will also help in the fight against HIV. Alexander Gintsburg, director of the Gamaleya Research Center for Epidemiology and Microbiology, spoke about this at the "Healthy Society" forum. "In less than three years of the pandemic, 7 million human lives were lost. If we look at excess mortality statistics, this number is not even 7 million, but 21 million. Humanity, naturally, cannot allow such a repetition, not to mention the colossal economic damage caused by this situation. Comprehensive preventive measures are being taken. First and foremost, the creation of vaccines to counter an as-yet-unknown Disease X."